LLY241220P715000
- 0.77
- -0.27-25.96%
Eli Lilly and Co Newsroom
Cash / Money Market reserves may reach 80 billion USD! Novo-Nordisk A/S (NVO.US) and Eli Lilly and Co (LLY.US) are expected to initiate a merger and acquisition frenzy.
Novo-Nordisk A/S and Eli Lilly and Co (LLY.US), two pharmaceutical giants that have achieved great success in the field of weight loss drugs, may trigger a wave of large-scale mergers and acquisitions in 2025.
INNOVENT BIO (01801.HK) and Eli Lilly and Co (LLY.US) have reached a commercialization agreement for "Jepalin" in mainland China.
INNOVENT BIO (01801.HK) and Eli Lilly and Co (LLY.US) announced a collaboration agreement regarding the rights of Eli Lilly’s non-covalent (reversible) BTK inhibitor "Jehpaili" (100 mg and 50 mg tablets) in mainland China. INNOVENT BIO will be responsible for the import, sale, promotion, and distribution of Jehpaili, while Eli Lilly will be responsible for the research and development and post-marketing medical affairs related work for Jehpaili. INNOVENT BIO's founder, Chairman and CEO Yu Dechao expressed great pleasure in further deepening the strategic cooperation with Eli Lilly, noting that Jehpaili is the latest generation, the first and only globally approved non-covalent (reversible) BTK inhibitor.
Behind the Scenes of Eli Lilly's Latest Options Trends
The Stock Market Is One Big Contradiction Right -2-
Lilly Endowment Donates $10 Million for American Red Cross Service to the Armed Forces
Lilly and EVA Pharma Announce Regulatory Approval and Release of Locally Manufactured Insulin in Egypt
Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com
Insurer Stocks Tumble. Trump Echoes Drug Industry Attacks on PBMs. -- Barrons.com
Moderna Remains the Most Shorted Among S&P 500 Healthcare Stocks in November
Express News | Trump: 'We're Going to Knock Out the Middlemen' Who Are Keeping Drug Prices High
Express News | Trump: Does Not Like Mandates for Vaccines, When Asked Whether Schools Should Mandate
Express News | Trump: Recently met with executives from Pfizer and Eli Lilly and Co.
Why the Investor Craze for Ozempic and Rival Weight-loss Drugs May Resume Next Year
Broadcom rises over 8% again, with a cumulative increase of over 35% in two days! Which company will become the next member of the "trillion Market Cap club"?
After Broadcom's market cap exceeded one trillion dollars, there are currently nine companies in the "trillion-dollar market cap club" in the U.S. stock market, namely Apple, Microsoft, NVIDIA, Amazon, Google, Meta, Tesla, Broadcom, and Taiwan Semiconductor.
The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com
EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease
INNOVENT BIO (01801) has reached a commercialization cooperation with Eli Lilly and Co regarding a new cancer drug based on BTK inhibitors.
On December 16, INNOVENT BIO (01801) and Eli Lilly and Co jointly announced the following cooperation agreement regarding Eli Lilly's non-covalent (reversible) BTK inhibitor, Jaypalta (100 mg and 50 mg tablets), in mainland China: INNOVENT BIO will be responsible for the import, sales, promotion, and distribution of Jaypalta; Eli Lilly will be responsible for the research and development as well as post-marketing medical affairs related work.
Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca (Pirtobrutinib) in Mainland China
Eli Lilly and Co's blockbuster new drug "Tirzepatide" has filed its fifth marketing application in China.
On December 14, the latest announcement on the CDE website states that Eli Lilly and Co (LLY.US) has had its new indication application for the blockbuster drug GIP/GLP-1 receptor dual agonist tirzepatide injection accepted.
Eli Lilly (NYSE:LLY) Is Increasing Its Dividend To $1.50